R35CA263814

Tackling undruggable cancer targets using chemoproteomic platforms - One of the biggest challenges facing cancer drug discovery is that >90% of the proteome is currently considered “undruggable” because most proteins do not possess known binding pockets or “ligandable hotspots” that can be pharmacologically and functionally targeted for therapeutic benefit.

Tackling the undruggable proteome requires the development of innovative technologies for ligand discovery and the discovery of novel therapeutic modalities to functionally manipulate the undruggable proteome for therapeutic benefit.

The Nomura Research Group is focused on reimagining drugability by advancing and applying chemoproteomic platforms to tackle the undruggable proteome, towards developing next-generation therapies and therapeutic modalities for cancer.

Regents Of The University Of California

TO PROVIDE FUNDAMENTAL INFORMATION ON THE CAUSE AND NATURE OF CANCER IN PEOPLE, WITH THE EXPECTATION THAT THIS WILL RESULT IN BETTER METHODS OF PREVENTION, DETECTION AND DIAGNOSIS, AND TREATMENT OF NEOPLASTIC DISEASES. CANCER BIOLOGY RESEARCH INCLUDES THE FOLLOWING RESEARCH PROGRAMS: CANCER CELL BIOLOGY, CANCER IMMUNOLOGY, HEMATOLOGY AND ETIOLOGY, DNA AND CHROMOSOMAL ABERRATIONS, TUMOR BIOLOGY AND METASTASIS, AND STRUCTURAL BIOLOGY AND MOLECULAR APPLICATIONS.

93.396 - Cancer Biology Research

National Cancer Institute (NCI) [HHS - NIH]

Berkeley, California 947202502 United States

Single Zip Code

NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) (PAR-21-333)

Amendment Since initial award the total obligations have increased 293% from $928,230 to $3,647,943.